# Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

> **NCT00678119** · PHASE2 · COMPLETED · sponsor: **Argos Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** AGS-003
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00678119
- **Lead sponsor:** Argos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678119, "Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00678119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*